Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Phathom Pharmaceuticals, Inc. plans to conduct an underwritten public offering of its common stock or pre-funded warrants, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The company intends to offer shares of its common stock or pre-funded warrants to certain investors [1] - The offering is subject to market conditions and other factors, with no assurance on completion or terms [1] - A shelf registration statement was filed with the SEC on January 7, 2026, which became effective automatically [3] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including working capital and R&D expenses [2] Group 3: Company Background - Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases [5] - The company has exclusive rights to vonoprazan, a potassium-competitive acid blocker, in the U.S., Europe, and Canada [5] - Vonoprazan is marketed in the U.S. for various gastrointestinal conditions, including heartburn and H. pylori infection [5]